Harbin Gloria Pharmaceuticals Co Ltd
SZSE:002437

Watchlist Manager
Harbin Gloria Pharmaceuticals Co Ltd Logo
Harbin Gloria Pharmaceuticals Co Ltd
SZSE:002437
Watchlist
Price: 2.68 CNY Market Closed
Market Cap: 6.1B CNY
Have any thoughts about
Harbin Gloria Pharmaceuticals Co Ltd?
Write Note

Harbin Gloria Pharmaceuticals Co Ltd
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Harbin Gloria Pharmaceuticals Co Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Harbin Gloria Pharmaceuticals Co Ltd
SZSE:002437
Revenue
ÂĄ2.4B
CAGR 3-Years
-8%
CAGR 5-Years
-15%
CAGR 10-Years
3%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Revenue
ÂĄ10.1B
CAGR 3-Years
5%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Revenue
ÂĄ10.9B
CAGR 3-Years
13%
CAGR 5-Years
15%
CAGR 10-Years
23%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Revenue
ÂĄ26B
CAGR 3-Years
-3%
CAGR 5-Years
3%
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Revenue
ÂĄ39.3B
CAGR 3-Years
2%
CAGR 5-Years
7%
CAGR 10-Years
8%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Revenue
ÂĄ561.9m
CAGR 3-Years
-18%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Harbin Gloria Pharmaceuticals Co Ltd
Glance View

Market Cap
6.1B CNY
Industry
Pharmaceuticals

Harbin Gloria Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines. The company is headquartered in Beijing, Beijing and currently employs 4,769 full-time employees. The company went IPO on 2010-06-23. The firm's products include cardiovascular and cerebrovascular drugs, orthopedic drugs, nutritional drugs, anti-infective drugs, immune-enhancing drugs, diabetes drugs, antineoplastic drugs and electrolytes drugs. The firm is also engaged in the agency, research and development of pharmaceuticals, the provision of clinical services and financial investment business. The firm distributes its products within domestic market and to overseas markets.

Intrinsic Value
2.32 CNY
Overvaluation 14%
Intrinsic Value
Price

See Also

What is Harbin Gloria Pharmaceuticals Co Ltd's Revenue?
Revenue
2.4B CNY

Based on the financial report for Sep 30, 2024, Harbin Gloria Pharmaceuticals Co Ltd's Revenue amounts to 2.4B CNY.

What is Harbin Gloria Pharmaceuticals Co Ltd's Revenue growth rate?
Revenue CAGR 10Y
3%

Over the last year, the Revenue growth was -11%. The average annual Revenue growth rates for Harbin Gloria Pharmaceuticals Co Ltd have been -8% over the past three years , -15% over the past five years , and 3% over the past ten years .

Back to Top